Compare Credo Technology Group Holding Ltd (CRDO) vs Hims and Hers Health Inc (HIMS) Price & Performance

CRDO trades at $212.42, down 3.45% today but maintains strong technical support near $204 with bullish moving averages. The company demonstrates exceptional fundamentals with 114.7% YoY revenue growth (Seeking Alpha, 2026-09-25) and 33.83% net margins, though valuation remains elevated at P/E of 74.6. Recent earnings beats and AI infrastructure demand drive positive sentiment.

Outlook remains positive given triple-digit revenue growth and $267.33 analyst price target (87.5% buy ratings), but premium valuation and customer concentration pose risks. The stock offers exposure to AI connectivity chip demand with potential for 26% upside to consensus target, though execution risks require monitoring.

Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.

The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.